APA

Harding F. A., Liu A. D., Stickler M., Razo O. J., Chin R., Faravashi N., Viola W., Graycar T., Yeung V. P., Aehle W., Meijer D., Wong S., Rashid M. H., Valdes A. M. & Schellenberger V. (20060130). A beta-lactamase with reduced immunogenicity for the targeted delivery of chemotherapeutics using antibody-directed enzyme prodrug therapy. : Molecular cancer therapeutics.

Chicago

Harding Fiona A, Liu Amy D, Stickler Marcia, Razo O Jennifer, Chin Regina, Faravashi Nargol, Viola Wendy, Graycar Tom, Yeung V Pete, Aehle Wolfgang, Meijer Daan, Wong Stephanie, Rashid M Harunur, Valdes Ana M and Schellenberger Volker. 20060130. A beta-lactamase with reduced immunogenicity for the targeted delivery of chemotherapeutics using antibody-directed enzyme prodrug therapy. : Molecular cancer therapeutics.

Harvard

Harding F. A., Liu A. D., Stickler M., Razo O. J., Chin R., Faravashi N., Viola W., Graycar T., Yeung V. P., Aehle W., Meijer D., Wong S., Rashid M. H., Valdes A. M. and Schellenberger V. (20060130). A beta-lactamase with reduced immunogenicity for the targeted delivery of chemotherapeutics using antibody-directed enzyme prodrug therapy. : Molecular cancer therapeutics.

MLA

Harding Fiona A, Liu Amy D, Stickler Marcia, Razo O Jennifer, Chin Regina, Faravashi Nargol, Viola Wendy, Graycar Tom, Yeung V Pete, Aehle Wolfgang, Meijer Daan, Wong Stephanie, Rashid M Harunur, Valdes Ana M and Schellenberger Volker. A beta-lactamase with reduced immunogenicity for the targeted delivery of chemotherapeutics using antibody-directed enzyme prodrug therapy. : Molecular cancer therapeutics. 20060130.